Home » Stocks » ALGS

Aligos Therapeutics, Inc. (ALGS)

Stock Price: $30.41 USD -2.45 (-7.44%)
Updated Jan 25, 2021 2:43 PM EST - Market open
Market Cap 1.25B
Revenue (ttm) n/a
Net Income (ttm) -73.06M
Shares Out 36.89M
EPS (ttm) -1.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $30.41
Previous Close $32.85
Change ($) -2.45
Change (%) -7.44%
Day's Open 33.50
Day's Range 29.47 - 33.91
Day's Volume 28,152
52-Week Range 13.20 - 34.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 month ago

Aligos (ALGS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to ...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing no...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to ...

Seeking Alpha - 3 months ago

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ARRY, CDAK, EBC, OPT, PRAX, SPEL, TARS
Market Watch - 3 months ago

Shares of Aligos Therapeutics Inc. rallied out of the gate Friday, as they opened 16% above the initial public offering price. The stock's first trade on the Nasdaq was at $17.40 at 1:33 p.m.

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its initial public offering of 10,000,000 shares of its c...

About ALGS

Aligos Therapeutics, a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-ß agonist for the treatm... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
CEO
Dr. Lawrence M. Blatt
Employees
73
Stock Exchange
NASDAQ
Ticker Symbol
ALGS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is 34.50, which is an increase of 13.47% from the latest price.

Price Target
$34.50
(13.47% upside)
Analyst Consensus: Buy